BioSpace News Archive

Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2021 second quarter on Wednesday, February 3, 2021 , after the market closes. Lannett management will host a conference call that same afternoon at 4:30 p.m. Eastern Time to review the company’s performance and answer questions.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that researchers in Dr. David Ho’s Columbia University lab and Regeneron scientists have independently confirmed that REGEN-COVTM (casirivimab and imdevimab antibody cocktail) successfully neutralizes the circulating SARS-CoV-2 variants first identified in the UK (B.1.1.7) and South Africa (B.1.351).

Bamlanivimab’s powerful neutralization of the virus responsible for COVID-19 provides therapeutic backbone for new therapies to expand protection against viral variants

Q BioMed Inc. (OTCQB: QBIO), announced today that the U.S. Food and Drug Administration’s Office of Orphan Products Development has granted Orphan Drug Designation to Uttroside-B , a small molecule chemotherapeutic for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

Heat Biologics, Inc.announces the publication of additional preclinical COVID-19 results in Frontiers in Immunology, a leading peer reviewed journal, which is available online.

electroCore, Inc., a commercial-stage bioelectronic medicine company, announced that gammaCore Sapphire has been included in a new long-term reimbursement policy launched by Matthew Whitty, Director of Innovation Research and Life Sciences and Chief Executive of the Accelerated Access Collaborative, for and on behalf of NHS England and NHS Improvement.

Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drug candidates for highly prevalent diseases, today announced initiation of an up to $14.5 million project funded by CARB-X to develop an oral monoclonal antibody cocktail to prevent serious diarrheal diseases.

Company recognized for developing the first-of-its-kind program designed to support employees, and boost the critically low number of living donor organ transplants

Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology.

PURE Bioscience, Inc. (OTCQB: PURE), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today announced the addition of three new members to the Board of Directors with the election of Kristin A. Taylor, David M. Rendall and Tom Myers. Ms. Taylor and Mr. Rendall also will serve on the audit and compensation committees of the Board of Directors.